Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:35 2022-11-25 am EST
39.26 EUR   +0.08%
11/11European Medicines Agency Panel Adopts Recommendation for Galapagos' Jyseleca Product Label
MT
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following extensive safety review of all JAK inhibitors
GL
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following extensive safety review of all JAK inhibitors
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Downgrades Galapagos to Equalweight From Overweight, Cuts Price Target to $61 From $80

09/09/2022 | 08:47am EST


ę MT Newswires 2022
All news about GALAPAGOS NV
11/11European Medicines Agency Panel Adopts Recommendation for Galapagos' Jyseleca Product L..
MT
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following exte..
GL
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following exte..
AQ
11/11Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca« Following..
CI
11/08Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study..
GL
11/08Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study..
AQ
11/08Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis st..
CI
11/07RBC Lowers Price Target on Galapagos to $53 From $55, Keeps Sector Perform Rating
MT
11/04Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
CI
11/04Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
GL
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2022 551 M 573 M 573 M
Net income 2022 -49,1 M -51,1 M -51,1 M
Net cash 2022 4 166 M 4 332 M 4 332 M
P/E ratio 2022 -93,1x
Yield 2022 -
Capitalization 2 585 M 2 688 M 2 688 M
EV / Sales 2022 -2,87x
EV / Sales 2023 -0,50x
Nbr of Employees 1 357
Free-Float 73,8%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 39,26 €
Average target price 55,00 €
Spread / Average Target 40,1%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-20.24%2 688
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918